Bone marrow transplant

What is a bone marrow transplant and how does it work?

A bone marrow transplant (medically termed a haematopoietic stem cell transplant, or HSCT) is an intensive medical procedure that replaces diseased, damaged, or non-functioning bone marrow with healthy blood-forming stem cells. Bone marrow is the spongy tissue inside large bones where red blood cells, white blood cells, and platelets are manufactured. When haematological malignancies, marrow failure syndromes, or severe genetic disorders prevent normal blood production, replacing these stem cells offers a pathway toward restoring normal haematopoiesis. International patients frequently evaluate options for a bone marrow transplant in Turkey within specialized inpatient units dedicated to complex oncology treatments in Turkey.

The physiological mechanism involves two primary phases: preparing the patient's body through conditioning, and infusing the healthy stem cells intravenously. The conditioning regimen uses targeted chemotherapy, sometimes accompanied by total body irradiation, to eliminate abnormal marrow cells and suppress the patient's immune system so it will not reject the new graft. Once infused, the healthy stem cells circulate through the bloodstream, migrate into the marrow cavities of bones, and begin producing new, healthy blood cells—a critical process known as engraftment. Understanding what is a bone marrow transplant requires recognizing that it is not a surgical organ transplant, but a biological reconstitution performed through cellular transfusion.

Get my free quote

Autologous vs allogeneic: how the main transplant types differ

Haematologists classify bone marrow transplants into two main biological categories depending on the origin of the stem cells: autologous and allogeneic. Choosing between these approaches depends on the underlying diagnosis, disease stage, overall organ function, and whether a compatible donor is available.

In an autologous transplant, the patient serves as their own donor. Stem cells are harvested from the patient's peripheral blood or marrow while the disease is in remission or under control, frozen in liquid nitrogen (cryopreserved), and stored. The patient then undergoes high-dose chemotherapy to destroy remaining disease cells, after which their stored stem cells are thawed and reinfused. Autologous procedures carry no risk of graft-versus-host disease (GvHD) because the immune cells recognise the body's tissues. They are standard consolidation therapies for conditions such as multiple myeloma and certain relapsed lymphomas.

In an allogeneic transplant, stem cells come from a healthy donor whose human leukocyte antigen (HLA) tissue markers closely match the recipient. Donors may be HLA-identical siblings, matched unrelated volunteers identified through global registries, or haploidentical (half-matched) family members such as parents or children. Allogeneic transplants provide an immunological benefit called the graft-versus-malignancy effect, in which donor immune cells actively seek out and eradicate residual cancer cells. However, they also introduce complex immunological risks that require months of immunosuppressive therapy.

Does a bone marrow transplant work? What clinical evidence shows

When patients ask does a bone marrow transplant work, haematological data show that it is an established, potentially curative modality for specific blood cancers and non-malignant marrow disorders, but clinical outcomes vary widely according to disease biology, patient age, remission status prior to conditioning, and donor matching precision.

Peer-reviewed registries, including the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), provide robust data regarding long-term survival and relapse rates across major indications:

• Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL): Allogeneic transplantation performed during first complete remission achieves durable, disease-free survival in a significant proportion of high-risk patients who would otherwise face near-certain relapse with conventional chemotherapy alone.
• Multiple myeloma: High-dose conditioning supported by autologous transplantation remains a cornerstone for eligible patients, reliably extending progression-free survival compared with standard maintenance regimens.
• Hodgkin and non-Hodgkin lymphomas: Autologous transplantation serves as standard salvage therapy for chemotherapy-sensitive relapses, while allogeneic approaches are reserved for multiply relapsed or refractory cases.
• Non-malignant disorders: Severe aplastic anaemia, thalassaemia major, and sickle cell disease can be definitively corrected through successful allogeneic engraftment, restoring healthy red blood cell production.

However, haematologists emphasize that transplantation is neither universally suitable nor devoid of serious hazards. Recurrence of the primary disease remains a possibility, and transplant-related mortality from infection, organ toxicity, or immune reactions means that clinical teams only recommend the procedure when potential therapeutic benefits clearly outweigh established risks.

Bone marrow transplant cost in Turkey compared with the UK, US and Germany

Financial considerations represent a significant factor for international families researching bone marrow transplant cost. Total expenditure depends on whether the transplant is autologous or allogeneic, donor source (related versus unrelated registry search), the duration of positive-pressure isolation hospitalization, and the intensive-care backup required. Families seeking a free quote can submit donor reports and bone marrow biopsies to receive an itemized estimate.

The comparative ranges below illustrate typical private self-pay figures across healthcare destinations. These are approximate institutional estimates, not binding individual quotes.

Several clinical elements influence the final bone marrow transplant price. Autologous procedures typically sit at the lower end of the range (€35,000 to €55,000 in Turkey), as they do not require international donor registry fees, extensive HLA typing of relatives, or long-term graft-versus-host disease management. Allogeneic transplants, particularly those involving unrelated donor acquisition through international registries or complex haploidentical protocols, require higher investment (€65,000 to €95,000 in Turkey).

A comprehensive international transplant package typically includes pre-transplant cardiac, pulmonary, and viral screening, donor workup and apheresis, conditioning chemotherapy, HEPA-filtered isolation room accommodation for three to six weeks, routine laboratory monitoring, essential supportive transfusions, standard antimicrobials, and initial outpatient monitoring. It generally excludes unforeseen intensive-care treatment, specialized biological pharmaceuticals for acute GvHD, and extended accommodation for accompanying family members outside the hospital.

Get my free quote

Who is an appropriate candidate for stem cell transplantation?

Eligibility for haematopoietic stem cell transplantation requires rigorous evaluation by a multidisciplinary haematology board. Candidate selection does not rely solely on chronological age, but on physiological fitness, disease biology, and specific scoring systems such as the Haematopoietic Cell Transplantation Comorbidity Index (HCT-CI).

Patients who may qualify as suitable candidates typically demonstrate:

• A confirmed haematological malignancy or bone marrow failure disorder that has shown responsive biology to induction therapy, ideally reaching complete remission or stable minimal disease burden.
• Adequate functional reserve of vital organs, specifically preserved left ventricular ejection fraction on echocardiography, satisfactory forced expiratory volume and diffusion capacity (DLCO) on pulmonary function tests, and intact renal and hepatic clearance.
• An acceptable performance status (such as an ECOG score of 0 to 1 or Karnofsky score above 70 to 80), reflecting physical independence in daily activities.
• Identification of a viable donor source (or adequate personal stem cell harvest yield) for allogeneic candidates.

Conversely, patients may be considered unsuitable if they present with active, uncontrolled systemic infections, severe irreversible organ damage (such as advanced heart failure, end-stage liver cirrhosis, or respiratory failure), refractory disease progressing rapidly despite salvage therapy, or psychosocial barriers that prevent strict adherence to prolonged isolation and complex medication schedules.

The transplant process step by step: conditioning to engraftment

Undergoing a transplant is a structured clinical journey lasting several weeks within a specialised isolation ward. The clinical path progresses through distinct operational stages:

1. Pre-transplant workup and stem cell harvesting

Both recipient and donor (in allogeneic cases) undergo exhaustive infectious disease screening, dental clearance, tissue typing, and organ assessment. For stem cell collection, growth factor injections (granulocyte colony-stimulating factor, or G-CSF) are administered over four to five days to mobilize stem cells from the bone marrow into circulating blood. The cells are collected via apheresis—a non-surgical blood-filtering procedure lasting three to four hours while the patient or donor rests comfortably. In rare cases, stem cells are harvested directly from the pelvic bone marrow under general anaesthesia.

2. Conditioning therapy

The patient is admitted to a dedicated room equipped with HEPA filtration and positive air pressure. Over several consecutive days, high-dose conditioning chemotherapy is administered to eradicate residual abnormal cells and create physical space in the bone marrow cavity for new graft cells.

3. Stem cell infusion (Day Zero)

Designated as Day Zero, the day of infusion resembles a standard blood transfusion. The collected stem cells are delivered through a central venous catheter directly into the bloodstream over one to two hours while vital signs are monitored. The patient remains awake and conscious throughout.

4. The neutropenic aplasia period

In the 10 to 20 days immediately following infusion, blood cell counts drop to near zero. During this phase, patients have neither neutrophils to fight bacterial infections nor platelets to prevent bleeding. The clinical team administers daily intravenous antibiotics, prophylactic antivirals and antifungals, and frequent red blood cell and platelet transfusions.

5. Engraftment

Engraftment occurs when the infused stem cells find their way into the marrow cavities, divide, and begin releasing new white cells, red cells, and platelets. Haematologists confirm engraftment once absolute neutrophil counts remain above 500 cells per microlitre for three consecutive days, typically between Day 14 and Day 21.

Bone marrow transplant recovery and trip timeline in Turkey

Planning a medical journey for a bone marrow transplant Turkey requires understanding that recovery is not measured in days, but across several months of progressive immune rebuilding. Patients undergoing bone marrow transplant in Turkey must plan for an extended overall stay of approximately two to three months (60 to 90 days).

The inpatient phase lasts between three and six weeks, during which the patient remains inside the hospital's HEPA-filtered unit until stable engraftment is verified, fever subsides, oral intake is established, and transfusion dependence decreases. Following hospital discharge, international patients must remain in nearby accredited outpatient accommodation in Turkey for an additional 4 to 8 weeks for frequent blood checks, electrolyte adjustments, and GvHD surveillance.

The broader bone marrow transplant recovery timeline unfolds over one to two years:

• Weeks 1 to 4: Inpatient isolation, intensive supportive care, monitoring for engraftment, and initial recovery from mucositis and gastrointestinal side effects.
• Weeks 5 to 12: Outpatient local monitoring, gradual weaning of intravenous infusions, initiation of oral immunosuppressive medications, and weekly clinic consultations.
• Months 3 to 6: Safe clearance to fly home once haematological stability is established, continuation of anti-infective prophylaxis, and transition to a local home haematologist.
• Months 6 to 12: Slow tapering of immunosuppressive drugs in allogeneic patients, progressive recovery of CD4+ T-cell and B-cell counts, and administration of re-vaccination schedules (childhood vaccines must be repeated).

Get my free quote

Bone marrow transplant before and after: evaluating therapeutic response

In cellular therapy, bone marrow transplant before and after does not refer to cosmetic visual changes, but to rigorous laboratory, cytogenetic, and radiological confirmation of disease eradication and biological reconstitution.

Before the transplant, baseline bone marrow aspirates, trephine biopsies, flow cytometry, and PET-CT imaging map the exact burden of malignant clones and cytogenetic mutations. After the transplant, evaluation focuses on three principal milestones:

• Haematological response: Verification that normal peripheral blood counts (haemoglobin, platelets, white cell differential) have returned to safe ranges without transfusion support.
• Chimerism analysis: In allogeneic recipients, molecular tests measure the percentage of blood cells originating from the donor versus recipient. Full donor chimerism (greater than 95 to 99 percent donor cells) confirms that the donor immune system has completely established itself.
• Measurable residual disease (MRD) negativity: Highly sensitive flow cytometry and next-generation sequencing assess whether single malignant cells survive in millions of examined marrow cells. Achieving MRD negativity correlates strongly with long-term remission.

Patients should recognize that physical recovery lags behind haematological numbers. Fatigue, altered taste, hair regrowth patterns, and mild peripheral stamina limitations often persist for six to twelve months while the immune system matures.

Comparing transplant approaches and non-transplant alternatives

Haematological care offers multiple therapeutic pathways. While solid tumours or isolated metastases may be addressed with techniques like radiofrequency ablation, haematological malignancies require systemic cell replacement or targeted molecular suppression. The table below outlines how primary transplant modalities compare with targeted cellular alternatives.

The determination of whether a patient benefits more from an autologous procedure, an allogeneic graft, or non-transplant targeted inhibitors is made by an oncology tumour board after reviewing genomic sequencing and previous chemotherapy response.

Potential risks, complications and graft-versus-host disease

Stem cell transplantation is a high-risk medical intervention that demands complete clinical transparency. Authoritative haematology bodies—including the National Health Service (NHS), the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT), and the American Society for Transplantation and Cellular Therapy (ASTCT)—document recognized complications associated with conditioning and engraftment.

Primary clinical risks include:

• Graft-versus-host disease (GvHD): Occurring only in allogeneic transplants, GvHD develops when donor T-cells recognize the recipient's organs as foreign. Acute GvHD typically manifests within the first 100 days, affecting the skin (rash), liver (elevated bilirubin), and gut (severe diarrhoea). Chronic GvHD can develop months later, causing scleroderma-like skin changes, dry eyes, oral inflammation, and joint tightness. Management requires careful adjustment of immunosuppressive drugs such as cyclosporine, tacrolimus, or corticosteroids.
• Severe infections: Because the immune system is severely compromised during and after conditioning, patients are vulnerable to opportunistic bacterial, fungal (such as Aspergillus or Candida), and viral infections (such as Cytomegalovirus, CMV, reactivation). Prophylactic medication and regular PCR monitoring are mandatory.
• Graft failure: In rare instances, donor stem cells fail to engraft, or the recipient's immune system rejects the graft, leaving the patient with persistent aplasia requiring a rescue transplant.
• Organ toxicities: High-dose conditioning drugs can cause mucositis (painful mouth and intestinal ulcers), sinusoidal obstruction syndrome (veno-occlusive disease of the liver), and interstitial lung injury.

Choosing a haematology centre: JACIE standards and red flags

Selecting an international hospital for a stem cell transplant requires evaluating clinical accreditation above all other considerations. The international gold standard for bone marrow transplantation is accreditation by the Joint Accreditation Committee ISCT-Europe & EBMT (JACIE). JACIE accreditation confirms that the clinical unit, apheresis collection team, and cell processing laboratory meet rigorous international quality management benchmarks.

When assessing a transplant facility, verify that the hospital provides:

• Dedicated positive-pressure isolation rooms with HEPA air filtration and laminar airflow to protect against fungal spores and airborne pathogens.
• An in-house apheresis laboratory, HLA tissue typing facility, and cryopreservation biobank.
• 24-hour on-site intensive care (ICU) support and an accredited blood bank capable of immediate irradiated, leukodepleted platelet and red cell delivery.
• A multidisciplinary team including adult or paediatric haematologists, infectious disease specialists, clinical nurse specialists, and transplant coordinators.

Red flags to avoid include centres that lack JACIE or JCI accreditation, facilities that offer transplants in general wards without HEPA isolation, clinics offering vague financial packages that omit transfusion or ICU costs, and providers promising guaranteed cure rates. Read our guide on how it works to understand international patient coordination, and request a preliminary haematology review through our free quote enquiry form.

Questions to ask the transplant haematologist:

• Is your transplant unit currently JACIE accredited for allogeneic and autologous procedures?
• How many transplants of my specific diagnosis does your haematology department perform annually?
• What type of isolation environment is used during the neutropenic phase, and how are airborne infections controlled?
• What is your centre's protocol if acute graft-versus-host disease or cytomegalovirus reactivation develops?
• What outpatient support and monitoring are provided in Turkey after hospital discharge, and who coordinates follow-up with my home haematologist?

Get my free quote

Hospitals with Oncology in Turkey

Academic Hospital

Üsküdar, Istanbul

MoHHealth Tourism Licence+2

Get Free Quote

Lokman Hekim Istanbul Hospital

Pendik, Istanbul

JCIMoH+2

Get Free Quote

View all

Frequently asked questions